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Background  and  aim: In  Mexico,  cancer  is  the  second  leading  cause  of  death  after  cardiovascu-
lar diseases,  and  colorectal  cancer  (CRC)  represents  4%  of  all  deaths  due  to  cancer.  More  than
80% of  patients  with  CRC  are  treated  in  tertiary  cancer  centers  with  advanced  tumors  (stages
III and  IV).  However,  there  is  no  colonoscopy-based  screening  program.  Our  primary  objective
was to  determine  the  prevalence  of  colorectal  neoplasm.
Materials  and  methods: A  prospective,  cross-sectional  study  was  conducted,  by  using  a  consec-
utive series  of  subjects  who  underwent  their  ﬁrst  colonoscopy  screening.  Patients  between  40
and 79  years  of  age  and  in  good  general  health  and  in  whom  colorectal  cancer  was  not  suspected
were included.
Results:  A  total  of  600  personal  letters  were  sent.  Of  these,  123  subjects  responded  to  the
invitation, of  which  14  were  excluded.  A  total  of  99  patients  completed  the  study,  73  (74%)
were women  and  26  (26%)  were  men,  with  a  mean  (±SD)  age  of  50.1  ±  7.41,  with  a  mean  BMI
of 27.20  ±  3.74  kg/m2.  Overall,  35  (35%)  patients  had  47  colorectal  neoplasm.  Among  these,
there were  25  adenoma  (9  were  advanced  adenoma)  in  17  (17%)  patients.  The  location  of
the lesions  was:  caecum  6.3%,  ascending  colon  8.5%,  transverse  19.1%,  descending  19.1%,  sig-
moid 21.2%,  and  rectum  25.5%.  There  was  a  trend  to  have  more  adenoma  in  men  (RR  =  2,
95%CI: 0.83--4.62,  p  =  .139).  In  conclusion,  the  prevalence  of  adenomas  detected  by  screening
colonoscopy  screening  in  the  Mexican  population  is  not  different  from  that  published  in  world
literature.
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México
Resultados  del  primer  programa  de  tamizaje  para  cáncer  colorrectal  en  México
Resumen
Antecedentes  y  objetivo:  En  México  el  cáncer  representa  la  segunda  causa  de  muerte  después
de las  enfermedades  cardiovasculares,  y  el  cáncer  colorrectal  (CCR)  representa  el  4%  de  todas
las muertes  debidas  a  cáncer.  Más  del  80%  de  los  pacientes  con  cáncer  colorrectal  son  detectados
y tratados  en  estadios  tardíos.  Actualmente  no  existe  un  programa  de  tamizaje  para  cáncer
colorrectal  en  nuestro  país.  Nuestro  objetivo  fue  determinar  la  prevalencia  de  las  neoplasias
colorrectales  en  una  muestra  de  pacientes  mexicanos.
Material  y  métodos: Se  realizó  un  estudio  prospectivo  y  transversal  con  pacientes  consecutivos
asintomáticos  quienes  se  sometieron  a  su  primera  colonoscopia  de  tamizaje.  Se  incluyeron
pacientes  entre  40  y  79  an˜os  de  edad  sin  ningún  datos  clínico  que  indicara  la  presencia  de
neoplasia  colorrectal.
Resultados:  Fueron  invitados  a  participar  un  total  de  600  sujetos  por  medio  de  cartas  person-
alizadas y  123  pacientes  respondieron  a  la  invitación.  Catorce  pacientes  fueron  excluidos.  Un
total de  99  pacientes  completaron  el  estudio:  73  (74%)  fueron  mujeres;  la  media  de  edad  fue
50.1 ±  7.41  an˜os,  con  un  IMC  de  27.20  ±  3.74  kg/m2.  En  total  35  (35%)  pacientes  tuvieron  47
neoplasias  colorrectales.  De  estas  lesiones,  25  fueron  adenomas  (9  fueron  adenomas  avanza-
dos) y  se  detectaron  en  17  pacientes.  La  localización  de  las  lesiones  fueron  en  ciego  el  6.3%,
en colon  ascendente  el  8.5%,  en  colon  transverso  el  19.1%,  en  colon  descendente  el  19.1%,
en colon  sigmoides  el  21.2%  y  en  recto  el  25.5%.  Se  observó  una  tendencia  a  la  presencia  de
mayor número  de  adenomas  en  los  hombres  (RR  =  2,  IC95%:  .83--4.62,  p  =  .139).  En  conclusión,
la prevalencia  de  adenomas  detectados  durante  una  colonoscopia  de  tamizaje  en  una  muestra
de población  mexicana  no  es  distinta  a  la  publicada  en  la  literatura  mundial.
© 2015  Asociación  Mexicana  de  Endoscopia  Gastrointestinal.  Publicado  por  Masson  Doyma  Méx-


















































n  2014,  the  American  Cancer  Society  (ACS)  estimates  that
36,830  new  cases  of  colorectal  cancer  (CRC)  will  be  diag-
osed  in  women  and  men,  and  50,130  individuals  will  die
rom  this  disease.1 CRC  incidence  and  mortality  rates  have
een  declining  for  the  past  two  decades,  largely  attributable
o  the  contribution  of  screening  to  prevention  and  early
etection.  First  guidelines  for  screening  and  surveillance
or  the  early  detection  of  adenomatous  polyps  and  CRC
n  average-risk  adults  were  published  in  19802 and  were
pdated  in  2008  in  an  evidence-based  consensus  process
hat  included  the  ACS,  the  US  Multi-Society  Task  Force  on
olorectal  Cancer  (USMSTF)  and  the  American  College  of
adiology  (ACR).3
Screening  options  may  be  chosen  based  on  individual  risk,
ersonal  preference  and  access.  Average-risk  adults  should
egin  CRC  screening  at  age  50  years  with  one  of  the  fol-
owing  options:  (1)  annual  high-sensitivity  fecal  occult  blood
est  (gFOBT)  or  fecal  immunochemical  test  (FIT);  (2)  ﬂexible
igmoidoscopy  (FSIG)  every  5  years;  (3)  colonoscopy  every  10
ears;  (4)  double-contrast  barium  enema  every  5  years,  or
5)  CT  colonography  every  5  years.
Data  suggest  that  the  incidence  in  younger  patients  is
ncreasing.4 Most  of  these  patients  have  no  risk  factors  that
ere  recognized  before  the  diagnosis.  In  some  studies,  such
ounger  persons  present  with  more  advanced  disease  and
ave  a  less  favorable  prognosis  than  older  persons  with
ewly  diagnosed  cancer.  The  yield  from  screening  of  persons
n
cn  younger  age  groups  has  been  investigated.5--7 However,
ot  enough  information  exists  regarding  colorectal  neoplasm
n  asymptomatic,  average-risk  persons  40--49  years  of  age.
In  Mexico,  cancer  is  the  second  leading  cause  of  death
fter  cardiovascular  diseases.  CRC  represents  4%  of  all
eaths  due  to  cancer,  with  a  speciﬁc  mortality  of  2.4  per
00,000  persons.  According  to  cancer  registry  data  updated
n  2002,  CRC  represents  3.8%  of  new  cancer  cases.8
An  increased  in  the  frequency  of  CRC  in  the  last  25  years
as  been  demonstrated.9 The  percentage  of  CRC  in  late
tages  is  high.  More  than  80%  of  patients  are  treated  in  ter-
iary  cancer  centers  with  advanced  tumors  (stages  III  and
V).10 Late  diagnosis  of  the  CRC  may  be  attributed  to  the
omplete  absence  of  screening  programs  and  contributes  to
he  low  survival  of  these  patients.
Although  the  reported  mortality  in  Mexico  is  less  than
/100,000  habitants,11 the  lowest  worldwide,  there  is  clear
isagreement  between  tumor  stage  at  diagnosis,  scarcity  of
esources  and  reported  mortality  particularly  due  to  the
oor  state  of  cancer  data  collection.  The  fragmentation
f  the  institutional  arrangements  contributes  to  poor  qual-
ty  of  statistical  data  available  in  Mexico.  The  incidence
nd  mortality  of  CRC  and  premalignant  lesions  in  2014  are
nknown.12
There  is  an  urgency  for  a  national  CRC  screening  pro-
ram;  however,  socio-cultural  and  economic  factors  have
egatively  inﬂuenced  the  initiative.
We  performed  a  cross-sectional  analysis  of  data  from  a

















































(Colorectal  cancer  screening  in  Mexico  
in  Mexico.  Our  primary  objective  was  to  determine  the
prevalence  of  colorectal  neoplasm.
Materials and  methods
A  cross-sectional  study  was  conducted  by  using  a  consecu-
tive  series  of  subjects  who  underwent  their  ﬁrst  colonoscopy
screening  as  part  of  an  employee-provided  wellness  pro-
gram  at  the  Medica  Sur  Hospital  in  Mexico  City,  between
2009  and  2010.  Potential  study  subjects  were  approached
by  an  invitation  letter  explaining  the  nature  of  the  study;
also,  public  announcements  were  posted  to  the  Hospital  web
site.  They  were  eligible  if  they  were  40--79  years  of  age
and  in  good  general  health  and  colorectal  cancer  was  not
suspected.  Informative  meetings  were  organized  to  explain
the  type  of  study  (objectives  of  the  study,  detailed  explana-
tion  of  a  colonoscopy).  Subjects  to  be  screened  received  a
standard  questionnaire,  including  questions  regarding  their
personal  medical  history  (including  history  of  colorectal  can-
cer  or  polyps),  current  medications,  family  history  (including
colorectal  cancer  or  polyps)  and  lifestyle  habits  (including
smoking  and  alcohol  consumption).  Personal  interviews  were
conducted  to  ensure  that  screenees  were  asymptomatic  (no
recent  changes  in  bowel  habits,  lower  abdominal  pain,  unex-
plained  weight  loss,  or  visible  rectal  bleeding).  Subjects
with  symptoms  were  urged  to  seek  medical  care  and  were
excluded  from  the  study.
We  excluded  the  subjects  with  previous  experience  with
colonoscopy,  sigmoidoscopy  or  barium  enema,  incomplete
questionnaire  answers.  To  ensure  that  the  population  was
of  average  risk,  we  excluded  individuals  who  had  a  per-
sonal  history  of  colorectal  neoplasm  or  inﬂammatory  bowel
disease  or  a  family  history  of  colorectal  neoplasm.  Written
informed  consent  was  obtained  from  each  participant.  The
study  was  approved  by  the  Institutional  Review  Board  of
Medica  Sur  Hospital.
Bowel  preparation  consisted  of  colonic  lavage  with  a
polyethylene  glycol  electrolyte  solution  (Nulytely®).
Sedation  was  administered  in  all  procedures  by  a  certiﬁed
anesthesiologist  with  the  combination  of  benzodiazepine
(midazolam  0.05  mg/kg)  and  propofol  (induction  doses
2  mg/kg  and  bolus  0.5  mg/kg).
Colonoscopy
All  colonoscopies  were  performed  by  only  one  experi-
enced  colonoscopist  by  using  a  UC-180HD  (Olympus).  During
colonoscopy,  the  location,  size,  number  and  appearance  of
colorectal  neoplasm  were  recorded.  Polyp  size  was  esti-
mated  by  using  open  biopsy  forceps,  and  polyps  shape  was
determined  according  to  the  Paris  classiﬁcation.13 All  polyps
seen  were  removed.  The  colonoscopist  recorded  the  extent
of  the  examination  and  the  quality  of  the  bowel  preparation
using  the  Boston  score.14
Biopsy  specimens  were  evaluated  locally  by  a  pathol-
ogist  using  the  criteria  established  by  the  World  Health
Organization.15The  duration  of  each  total  examination  was  recorded  as
well  as  the  duration  of  withdrawal.
The  30-day  data  for  complications  and  death  from




easurement  and  deﬁnitions
n  advanced  neoplasm  was  deﬁned  as  a  cancer  or  adenoma
hat  was  at  least  10  mm  in  diameter  and  had  high-grade  dis-
lasia,  villous  or  tubulovillous  histological  characteristics,
r  any  combination  thereof.
According  to  the  recommendations  of  the  World  Health
rganization,  body  mass  index  (BMI)  was  categorized  as  fol-
ows:  normal  (<25  kg/m2),  overweight  (≥25  y  <30  kg/m2)  and
bese  (≥30  kg/m2).
Proximal  adenomas  were  deﬁned  as  those  occurring  in
he  cecum,  ascending  colon,  hepatic  ﬂexure  and  transverse
olon.  Distal  adenomas  were  those  occurring  in  the  splenic
exure,  descending  colon,  sigmoid  colon  and  rectum.
tatistical analysis
ontinuous  variables  were  expressed  as  the  mean  ±  standard
eviation,  and  categorical  variables  were  presented  as
bsolute  values  and  percentages.  The  differences  between
ontinuous  variables  were  analyzed  by  using  the  unpaired
tudent  t test,  and  differences  between  categorical  varia-
les  were  analyzed  by  using  the  X2 test  and  the  Fisher  exact
est  as  appropriate.  The  relationship  between  age  group
nd  the  prevalence  of  colorectal  neoplasm  was  analyzed
or  trends  by  using  the  X2 test.  A  p  value  <  0.05  was  consid-
red  to  indicate  statistical  signiﬁcance.  The  analyses  were
erformed  with  SPSS  software,  version  17.0.
esults
 total  of  600  personalized  letters  were  sent  to  employees
f  Medica  Sur  Hospital.  Of  these,  123  subjects  responded
o  the  invitation.  We  excluded  14  subjects.  The  reasons  for
xclusion  were:  previous  colonoscopy,  use  of  anticoagulants,
nd  lower  gastrointestinal  bleeding.  Three  subjects  did  not
ccept  to  participate  and  seven  did  not  attend  to  the  pro-
edure.  A  total  of  99  patients  completed  the  study,  73  (74%)
ere  women  and  26  (26%)  were  men,  with  a  mean  (±SD)  age
f  50.1  ±  7.41,  with  a  mean  of  BMI  of  27.20  ±  3.74  kg/m2.
hirty-seven  patients  had  at  least  one  comorbidity,  and  the
ost  frequent  was  high  blood  pressure.  Colonoscopy  to  the
ecum  was  performed  in  all  patients,  and  terminal  ileum  was
ntubated  in  87  (87%)  cases.  The  mean  bowel  preparation
core  was  7.91  ±  .84.  The  mean  duration  of  withdrawal  was
.43  ±  3.34  min.  The  demographics  of  the  subjects  included
n  the  analysis  according  to  the  colonoscopy  result  are  listed
n  Table  1. Overall,  35  (35%)  patients  had  47  colorectal
eoplasm.  Among  these,  there  were  25  adenoma  (9  were
dvanced  adenoma)  in  17  (17%)  patients.  Fig.  1  shows  images
f  polyps  found  during  colonoscopies  and  one  image  of  a
olypectomy.  Table  2  shows  the  prevalence  of  colorectal
eoplasm  throughout  the  colon.  The  location  of  the  lesions
as:  cecum  3  (6.3%),  ascending  colon  4  (8.5%),  transverse  9
19.1%),  descending  9  (19.1%),  sigmoid  10  (21.2%)  and  rec-
um  12  (25.5%).  The  median  size  of  the  neoplasm  was  4  mm
range  2--20).  The  prevalence  of  adenomas  was  analyzed  by
ge  group  (Table  3),  showing  higher  prevalence  at  older  age
Fig.  2).
The  demographics  of  the  subjects  were  analyzed  accord-
ng  to  the  presence  of  adenoma  and  advanced  adenoma,  and
62  S.  García-Osogobio  et  al.
Table  1  Demographics  of  the  subjects  included  in  the  anal-
ysis according  to  the  colonoscopy  result.
Normal
colonoscopy




n  =  35
n  (%)
p  value
Gender,  women  48  (75)  25  (71)  0.81
Comorbidities  21  (33)  16  (46)  0.27
Complete
colonoscopy
64 (100)  35  (100)  NC
X ±  DE X  ±  DE
Bowel  preparation 7.95  ±  .82 7.83  ±  .89 .628
Withdrawal  time,
min
6.22  ±  1.83 9.64  ±  4.33 .000
Age, years  46.89  ±  6.29  54.14  ±  7.69  .000
BMI 27.07  ±  3.90  27.43  ±  3.48  .651
BMI: bowel mass index (kg/m2).
Table  2  Prevalence  of  colorectal  neoplasm  throughout  the
colon.
n  =  47
n  (%)
Tubular  adenoma  23  (49)
Hyperplastic  polyp 13  (28)
Chronic  colitis 8  (17)
Tubulovillous  adenoma 1  (2)
Villous adenoma 1  (2)
Fibrolipoma  1  (2)
Table  3  Prevalence  of  adenomas  analyzed  by  age  group.
No  adenoma
n  =  82
n  (%)
Adenoma
n  =  17
n  (%)
p  value
























potential  beneﬁt  from  adenoma  removal.  Unfortunately,  in50--59  years  30  (37)  9  (53)
60--69  years  5  (6)  6  (35)
o  difference  was  found;  however,  there  is  a  trend  to  have
ore  adenoma  in  men  (RR  =  2,  IC95%  .83--4.62,  p  =  .139).
No  complication  was  documented  in  any  patient.
iscussion
ur  data  provide  the  ﬁrst  information,  to  our  knowledge,
n  the  prevalence  of  colorectal  neoplasia  in  asymptomatic
ersons  in  Mexico.  This  study  found  that  the  prevalence  of
olorectal  neoplasia  was  35%.  Speciﬁcally,  the  prevalence  of
denomas  was  17%.  Adenomas  were  more  common  among
en  than  women  (26.9%  vs  13.69%),  and  the  prevalence
f  detected  adenomas  increased  markedly  with  age-group
40--49  years  vs  50--59  years).  According  to  location  of  ade-
omas,  there  was  no  difference  between  proximal  and  distal
olon  (7%  vs  10%).
Current  guidelines  suggest  that  adenomas  should  be
etected  in  ≥15%  of  women  and  in  ≥25%  of  men  who  undergo
M
i
nigure  1  Polyps  found  during  colonoscopies  and  snare
olypectomy.
creening  colonoscopy;16 however,  these  estimates  were
btained  from  small  referral  populations.  Data  on  the  preva-
ence  of  adenomas  detected  in  diverse  populations  from
arge  community  based  sources  estimate  lower  prevalence
n  women  than  in  men  (20.2%  vs  30.6%).17 Adenoma  preva-
ence  has  been  used  to  estimate  cancer  risk  and  to  identify
hich  demographic  populations  may  experience  the  highestexico  there  is  not  a  national  screening  program  even  know-
ng  that  CRC  is  the  most  frequent  cancer  within  digestive
eoplasias.9 We  believe  that  our  data,  which  are  not  far  from
















17. Corley DA, Jensen CD, Marks AR, et al. Variation of adenomaAdenoma
Figure  2  Prevalence  of  adenomas  by  age  group.
the  world  data,  could  play  an  important  role  to  initiate  a  CRC
screening  program.  Although  there  are  no  previous  data  of
CCR  screening  in  our  population,  our  data  showed  here  are
similar  to  that  previously  reported  in  others  populations.
Strengths  of  the  current  study  include  the  prospective
nature,  the  inclusion  of  only  asymptomatic  patients,  its
use  of  validated  approaches  to  screening  examinations  and
pathology  data,  information  on  polyp  size,  details  of  bowel
preparation  and  extent  of  exam.
The  principal  limitation  of  this  study  is  the  small  sample
size  and  single-center  participation.  However,  we  have  to
mention  that  our  results  represent  the  ﬁrst  information  in
this  topic  from  a  private  center  from  Mexico  and  even  from
Latin  America;  because  of  that  we  are  sure  that  these  results
are  of  big  importance  for  future  revisions.
In  conclusion,  the  prevalence  of  adenomas  detected  at
screening  colonoscopy  is  not  different  to  that  published  in
world  literature.  The  current  results  provide  the  most  pre-
cise  data  available  on  the  prevalence  of  adenomas  in  Mexico.
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